Journal of ophthalmic & vision research · 2026
One-year Success Rate of Selective Laser Trabeculoplasty in Pseudoexfoliative Glaucoma: A Prospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Motlagh Behzad Fallahi, Arasteh Amin, Mostafaie Ali, Ghalamara Hakimallah, Najafzadeh Farhad
Аннотация
PURPOSE: To evaluate the 1-year effectiveness of selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG).
METHODS: This prospective, single-arm, non-randomized interventional study involved 40 eyes from 40 patients with PEXG with no history of glaucoma surgery and laser trabeculoplasty. All participants underwent a single session of 360º SLT. Follow-up visits were conducted at 2 hours, 1 day, 1 week, and at 1, 2, 3, 4, 5, 6, and 12 months after the procedure. The intraocular pressure (IOP), the number of anti-glaucoma medications (NOM), and the 1-year success rate were investigated as primary outcome measures; while the incidence of adverse effects was considered the secondary outcome. Treatment success was defined as a ≥ 20% decrease in IOP compared to baseline.
RESULTS: The baseline IOP was 22.19 ± 2.08 mmHg, and the mean NOM was 3.12 ± 0.55 before the SLT procedure. The mean IOP was significantly lower at all follow-up visits than at baseline, whereas the mean NOM remained unchanged throughout the follow-up period. The mean IOP values at 1, 3, 6, and 12 months after SLT were 18.02, 16.92, 16.47, and 15.31 mmHg, respectively. The overall 1-year success rate was 85%, with an average IOP reduction of 31.0% relative to baseline. The most common adverse event following SLT was mild anterior chamber inflammation, which occurred in 32.5% of eyes.
CONCLUSION: The SLT procedure could significantly reduce IOP in patients with PEXG with minimal adverse effects. The 1-year outcomes were favorable, suggesting that SLT may serve as an effective primary or complementary treatment for PEXG.
METHODS: This prospective, single-arm, non-randomized interventional study involved 40 eyes from 40 patients with PEXG with no history of glaucoma surgery and laser trabeculoplasty. All participants underwent a single session of 360º SLT. Follow-up visits were conducted at 2 hours, 1 day, 1 week, and at 1, 2, 3, 4, 5, 6, and 12 months after the procedure. The intraocular pressure (IOP), the number of anti-glaucoma medications (NOM), and the 1-year success rate were investigated as primary outcome measures; while the incidence of adverse effects was considered the secondary outcome. Treatment success was defined as a ≥ 20% decrease in IOP compared to baseline.
RESULTS: The baseline IOP was 22.19 ± 2.08 mmHg, and the mean NOM was 3.12 ± 0.55 before the SLT procedure. The mean IOP was significantly lower at all follow-up visits than at baseline, whereas the mean NOM remained unchanged throughout the follow-up period. The mean IOP values at 1, 3, 6, and 12 months after SLT were 18.02, 16.92, 16.47, and 15.31 mmHg, respectively. The overall 1-year success rate was 85%, with an average IOP reduction of 31.0% relative to baseline. The most common adverse event following SLT was mild anterior chamber inflammation, which occurred in 32.5% of eyes.
CONCLUSION: The SLT procedure could significantly reduce IOP in patients with PEXG with minimal adverse effects. The 1-year outcomes were favorable, suggesting that SLT may serve as an effective primary or complementary treatment for PEXG.